Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 44

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---
Share-based compensation

			-

			-

			-

			-

			443,559

			-

			-

			443,559

			Net loss and comprehensive loss

			-

			-

			-

			-

			-

			(10,143
			)

			(5,207,994
			)

			(5,218,137
			)

			Balance - June 30, 2024

			3,247,389

			$
			47,236,024

			$
			-

			$
			-

			$
			13,482,824

			$
			(224,791
			)
			 
			$
			(57,626,962
			)
			 
			$
			2,867,095

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

6

Edesa Biotech, Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

1. Nature of Operations

Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.

The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “EDSA”.

Going Concern

These unaudited condensed consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months.

For the nine months ended June 30, 2025, the Company incurred a comprehensive loss of $4.8 million resulting in an accumulated deficit of $63.6 million. For the nine months ended June 30, 2025, the Company had a net cash outflow from operating activities of $5.6 million and ended the period with $12.4 million in cash and cash equivalents and a working capital of $12.1 million. During the nine month period ended June 30, 202